Enter multiple symbols separated by commas

Novacea Shares Double on Licensing Deal with Schering-Plough

Biotechnology company Novacea and drug developer Schering-Plough said they signed a licensing agreement for prostate cancer treatment candidate Asentar. Novacea shares jumped as much as $9.19 or 114% to $17.25 before giving back some of the gains .

South San Francisco, Calif.-based Novacea, which is conducting late-stage studies on the drug candidate, will receive an upfront payment of $60 million, including a $35 million reimbursement for past research and development expenses. It will also receive a license fee of $25 million and a commitment from Schering-Plough to buy $12 million in Novacea common stock.

Novacea has the potential to receive pre-commercial milestone payments of up to $380 million and future royalties, the company said.

Schering-Plough will be responsible for all "forward development" costs and will fund commercialization of the drug.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Lottery ticket

    A thief who broke into the car of a Seattle couple left behind a million-dollar lottery ticket, NBC News reports.

  • The Lamborghini SpA Urus SUV.

    There's no shortage of luxury vehicle choices, but increasingly the wealthy are opting for high-end SUVs instead of traditional models.

  • Mike Trout #27 of the Los Angeles Angels takes a picture with fans before a game with Boston Red Sox at Fenway Park on May 23, 2015 in Boston, Massachusetts.

    MLB is using digital media initiatives like Snapchat and Web video to connect with younger viewers. Is it enough?

U.S. Video